Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Hematology
Disease Category: Von Willebrand Disease
Trial Information
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P, Antihemophilic Factor/Von Willebrand Factor Complex)
The purpose of this study is to test the safety and
effectiveness of Humate-P, a drug that is not approved by the Food
& Drug Administration (FDA) for the treatment of patients with
congenital (existing at birth) von Willebrand Disease (vWD), an
inherited bleeding disorder, in surgery.
Humate-P is currently approved by the FDA (Food and Drug
Administration) in the United States for the treatment of
Hemophilia A and for the treatment or prevention of bleeding in vWD
patients.
No Compensation Provided
Patient Inclusion/Exclusion Criteria:
You must have a diagnosis of a vonWillebrand Disease (vWD).
There is no age limit to enroll in the study and you must be having
elective surgery requiring Humate-P to control the bleeding.
Emergency surgery and a history of allergic reaction to
Humate-P.
Johanna Mccarthy
Mount Sinai Medical Center
One Gustave L. Levy Place
New York NY 10029
Phone: 212-241-3935
Fax: 212-722-6079
EMail: johanna.mccarthy@mssm.edu
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
